AHA GUIDELINES Bundle (free trial)

Blood Cholesterol

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512420

Contents of this Issue

Navigation

Page 28 of 31

29 M A N U S C R I P T Figure 3. Cost-Effectiveness Analysis for PCSK9 Inhibitors Figure 3. Cost-Effectiveness Analysis for PCSK9 Inhibitors Conceptual relationship between the clinical effectiveness of PCSK9 inhibitor therapy, measured in QALYs added compared with statin therapy, on the horizontal axis, and their clinical value, measured in dollars per QALY added, on the vertical axis. e top curve indicates the relationship at full U.S list price of PCSK9 inhibitor therapy ($14,000/y), the middle curve indicates the relationship if the price were reduced by 50% (i.e., to $7,000/y), and the bottom curve indicates the relationship if the price were reduced by 75% (i.e., to $3,500/y). Reproduced from Hlatky et al. J Am Coll Cardiol. 2017;70:2677-87.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Blood Cholesterol